Evidence map›Paper›PMID 38227963›Full record

Trial reportThe American journal of tropical medicine and hygiene2024

Gut Microbiome Diversity and Antimicrobial Resistance After a Single Dose of Oral Azithromycin in Children: A Randomized Placebo-Controlled Trial.

Thuy Doan, Zijun Liu, Ali Sié, Clarisse Dah, Mamadou Bountogo, Mamadou Ouattara, Boubacar Coulibaly, Dramane Kiemde, Guillaume Zonou, Eric Nebie and 10 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of tropical medicine and hygiene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Thuy DoanFrancis I. Proctor Foundation, University of California, San Francisco, California.
Zijun LiuDepartment of Ophthalmology, University of California, San Francisco, California.
Ali SiéCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Clarisse DahCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Mamadou BountogoCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Mamadou OuattaraCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Boubacar CoulibalyCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Dramane KiemdeCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Guillaume ZonouCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Eric NebieCentre de Recherche en Santé de Nouna, Nouna, Burkina Faso.
Jessica BrogdonFrancis I. Proctor Foundation, University of California, San Francisco, California.
Elodie LebasFrancis I. Proctor Foundation, University of California, San Francisco, California.
Armin HinterwirthFrancis I. Proctor Foundation, University of California, San Francisco, California.
Lina ZhongFrancis I. Proctor Foundation, University of California, San Francisco, California.
Cindi ChenFrancis I. Proctor Foundation, University of California, San Francisco, California.
Zhaoxia ZhouFrancis I. Proctor Foundation, University of California, San Francisco, California.
Travis PorcoFrancis I. Proctor Foundation, University of California, San Francisco, California.
Benjamin F ArnoldFrancis I. Proctor Foundation, University of California, San Francisco, California.
Catherine E OldenburgFrancis I. Proctor Foundation, University of California, San Francisco, California.
Thomas M LietmanFrancis I. Proctor Foundation, University of California, San Francisco, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mass antibiotic distribution to preschool children resulted in alterations of the gut microbiome months after distribution. This individually randomized, placebo-controlled trial evaluated changes in the gut microbiome and resistome in children aged 8 days to 59 months after one dose of oral azithromycin in Burkina Faso. A total of 450 children were randomized in a 1:1 ratio to either placebo or azithromycin. Rectal samples were collected at baseline, 2 weeks, and 6 months after randomization and subjected to DNA deep sequencing. Gut microbiome diversity and normalized antimicrobial resistance determinants for different antibiotic classes were evaluated. Azithromycin decreased gut bacterial diversity (Shannon P < 0.0001; inverse Simpson P < 0.001) 2 weeks after treatment relative to placebo. Concurrently, the normalized abundance of macrolide resistance genetic determinants was 243-fold higher (95% CI: 76-fold to 776-fold, P < 0.0001). These alterations did not persist at 6 months, suggesting that disruptions were transient. Furthermore, we were unable to detect resistance changes in other antibiotic classes, indicating that co-resistance with a single course of azithromycin when treated at the individual level was unlikely.

Indexed as

AzithromycinGastrointestinal MicrobiomeAnti-Bacterial AgentsChild, PreschoolDrug Resistance, BacterialHumansMacrolidesAnti-Bacterial AgentsAzithromycinMacrolides

Identifiers

PMID38227963
PMCPMC10859792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.